Rani Therapeutics Holdings, Inc.
NASDAQ:RANIBiotechnology
-$0.04 today
- Market cap
- $52.19M
- Beta
- 0.76
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$0.16
Volume 0.23M
Average 1.15M
RANI Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Rani Therapeutics Holdings, Inc.NASDAQ: RANI
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income growth accelerates
Q1 FY2026 net income of $8.02M (cash outflow) rose 10.3% year over year, ahead of the -25.4% change in trailing-twelve-month net income. Sequentially, it fell 11.7% from the prior quarter. Over 3 fiscal years it compounded at -22.3% a year.
Context
- Net income amounted to 1817.1% of revenue in FY2025, down 3687.2 pp from a year earlier.
- Net income grew in size in 1 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 3 analysts of -$10.78M (-63.7%) for the fiscal year ending Dec 2026, a slowdown from the -47.6% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$8.02M-11.7% QoQ
- Last fiscal yearDec 2025
- -$29.67M-47.6% YoY
- LTMMar 2026
- -$31.7M-25.4% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +10.3% | +39.8% | +29.5 pp |
| 1 year | -47.6% | -63.7% | -16.1 pp |
| 3-year CAGR | -22.3% | -27.9% | -5.5 pp |
| 5-year CAGR | -25.2% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (29.67M) USD
- Year-over-year change
- +47.6%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (29.67M) | +47.6% |
| FY2024 | 2024-12-31 | (56.58M) | -66.6% |
| FY2023 | 2023-12-31 | (33.97M) | +46.4% |
| FY2022 | 2022-12-31 | (63.34M) | -660.3% |
| FY2021 | 2021-12-31 | (8.33M) | — |
Net Income vs competitors
How RANI compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -25.4% is the lowest of 9, against a peer median of +9.8%.
- Net income amounts to 1000.2% of revenue for RANI, versus a peer median of 1764.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $147.39M USD | +11.7% | +4.0% | 839.5% | |
| LTM Mar 2026 | $123.33M USD | +55.2% | -13.9% | 356.9% | |
| LTM Mar 2026 | $84.53M USD | +68.1% | +22.9% | — | |
| LTM Mar 2026 | $68.36M USD | +31.7% | +2.6% | 3832.0% | |
| LTM Mar 2026 | CHF 64.16M CHF | +7.8% | — | — | |
| FY2025 | €49.18M EUR | -0.6% | -5.4% | 1764.5% | |
| LTM Mar 2026 | $44.76M USD | -8.4% | +5.8% | 8526.1% | |
ELTXElicio Therapeutics, Inc. | LTM Mar 2026 | $40.19M USD | -21.6% | +11.9% | — |
| LTM Mar 2026 | $31.7M USD | -25.4% | -22.3% | 1000.2% | |
| Peer median (excluding RANI) | — | +9.8% | +4.0% | 1764.5% | |
Competitors are the stored peer set for RANI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (8.33M) | (63.34M) | (33.97M) | (56.58M) | (29.67M) |
| Depreciation & Amortization | 497K | 548K | 822K | 1.03M | 900K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 22.6M | 15.78M | 19.01M | 16.03M | 11.8M |
| Change in Working Capital | (3.43M) | 509K | (2.14M) | (544K) | 6.96M |
| Accounts Receivables | 0 | 0 | 0 | (428K) | (1.61M) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 543K | 163K | (595K) | 711K | (1.05M) |
| Other Working Capital | (3.97M) | 346K | (1.55M) | (827K) | 9.62M |
| Other Non-Cash Items | (43.58M) | (10K) | (34.96M) | 4.57M | (8.7M) |
| Operating Cash Flow | (32.25M) | (46.52M) | (51.24M) | (35.5M) | (18.71M) |
| Capital Expenditures | (506K) | (1.62M) | (1.23M) | (268K) | (88K) |
| Acquisitions (Net) | 0 | (851K) | 0 | 0 | 0 |
| Purchases of Investments | 0 | (73.82M) | (73.26M) | (58.72M) | (33.97M) |
| Sales of Investments | 0 | 3M | 104.35M | 77.55M | 26.75M |
| Other Investing Activities | 0 | 851K | 0 | 1.25M | 278K |
| Investing Cash Flow | (506K) | (72.44M) | 29.86M | 19.81M | (7.03M) |
| Debt Repayment | (2.85M) | 29.57M | 0 | (5M) | (20.72M) |
| Common Stock Issued | 73.65M | 317K | 395K | 18.63M | 61.08M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 26K | (886K) | (162K) | (47K) | (59K) |
| Financing Cash Flow | 77.15M | 29.01M | 233K | 13.59M | 40.3M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 44.4M | (89.95M) | (21.14M) | (2.1M) | 14.56M |
| Free Cash Flow | (32.75M) | (48.13M) | (52.47M) | (35.76M) | (18.8M) |
Rani Therapeutics Holdings, Inc.
NASDAQ:RANI
Intrinsic Alpha fair value
Locked
Current Price
$0.80
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.